- Price
- 8.94
- Open
- 8.84
- High
- 8.94
- Low
- 8.84
- Volume
- 17,263
- Currency
- GBX
Delayed data · Source: Aquis Stock Exchange
| 6 Aug 2026 | 07:00:05 | Unaudited Interim Results to 30 June 2026 |
| 23 Jul 2026 | 07:00:05 | New Partnership Agreement in Belgium |
| 23 Jun 2026 | 13:00:00 | Result of AGM |
| 1 Jun 2026 | 07:00:09 | New Partnership Agreement in Slovakia |
| 29 May 2026 | 07:00:04 | Notice of AGM |
ProBiotix Health Plc develops probiotic formulations aimed at supporting cardiometabolic health. The company operates within the dietary supplement sector, focusing on preventative health solutions that leverage its proprietary probiotic strain, LPLDL®. ProBiotix partners with dietary supplement suppliers and consumer health companies globally to provide private label and turnkey probiotic products. Its operations span multiple regions, including Europe, the United States, and China, targeting markets driven by trends in healthy aging and cardiovascular health.
| 6 Aug 2026 | 07:00:05 | Unaudited Interim Results to 30 June 2026 |
| 23 Jul 2026 | 07:00:05 | New Partnership Agreement in Belgium |
| 23 Jun 2026 | 13:00:00 | Result of AGM |
| 1 Jun 2026 | 07:00:09 | New Partnership Agreement in Slovakia |
| 29 May 2026 | 07:00:04 | Notice of AGM |
ProBiotix Health Plc develops probiotic formulations aimed at supporting cardiometabolic health. The company operates within the dietary supplement sector, focusing on preventative health solutions that leverage its proprietary probiotic strain, LPLDL®. ProBiotix partners with dietary supplement suppliers and consumer health companies globally to provide private label and turnkey probiotic products. Its operations span multiple regions, including Europe, the United States, and China, targeting markets driven by trends in healthy aging and cardiovascular health.